Cipla has announced the launch of Yurpeak® (tirzepatide), a once-a-week injectable treatment designed to help manage both obesity and type 2 diabetes — two health issues that are growing rapidly in India. The company will distribute and promote Yurpeak® in the country, following Lilly’s DCGI approval for the product. This makes Yurpeak® the second tirzepatide brand available from Lilly in India.
Tirzepatide is the first therapy that activates both GIP and GLP-1 receptors, helping improve blood sugar levels while also supporting meaningful weight loss. It is recommended along with diet and exercise for adults with type 2 diabetes, as well as for chronic weight management in those who are obese (BMI of 30 or higher) or overweight (BMI of 27 or above) with at least one weight-related condition.
Yurpeak® will be available only on prescription and will come in the easy-to-use KwikPen® device. Patients will have access to six dosing strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — giving doctors flexibility to tailor the treatment as needed.
